(NYSE American: NNVC) Shares Key Announcement This Morning (Multiple Technicals Triggered)

*Sponsored

May 22nd

Greetings, Friend!

NanoViricides, Inc. (NYSE American: NNVC) continues to hold the top spot on my watchlist early Thursday for multiple reasons.

First off, the company shared a key announcement this morning.

Check it out here: The New Rational FDA CVD Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

From the article:

"Evidence-based decision making about vaccine boosters policy for CVD is a welcome change over broadcast vaccine recommendation for all," commented Anil R. Diwan, Ph.D., President and Executive Chairman of NanoViricides, adding, "This rational and scientific, non-dogmatic approach should go a long way towards restoring public trust in institutions that make decisions that affect peoples' lives."

On top of the news, NNVC continues to have 8 triggered technical indicators over at Barchart including the website's composite "Trend Seeker" indicator.

Plus, with a low float of fewer than 16Mn shares, volatility potential could be heightened on a daily basis.

Take a moment to read my initial report quickly and then consider (NYSE American: NNVC) for your radar.

-----

We're watching a potential breakout idea currently flying under-the-radar on the NYSE American.

So, what's special about this one?

First off, they are a cutting-edge biopharmaceutical company who has just completed a successful Phase I clinical trial for its innovative broad-spectrum antiviral, NV-387, with no adverse events reported, raising hopes for a new era in combating viral pandemics.

They're also strategically advancing NV-387 into Phase II trials targeting M-P-ox in Central Africa, while also preparing for future studies against influenza, RSV, and other high-impact viral threats.

With a robust intellectual property portfolio and a unique technology platform, this enterprise is positioning itself at the forefront of antiviral innovation—leaving the world to wonder what breakthrough will come next.

And registering fewer than 16Mn shares in its float, volatility potential could be extremely present for this profile on a daily basis.

With an aim to disrupt multiple, Bn dollar markets, this company has eluded Wall Street's attention for the time being.

But for how much longer, that's tough to say.

As this company powers forward in 2025 and beyond, it may just be a matter of time until they become a household name as global health uncertainties could propel their game-changing work into the spotlight.

Hitting #1 on my watchlist this week, it may be time to consider this breakout idea for your radar:

*NanoViricides, Inc. (NYSE American: NNVC)*

NanoViricides, Inc. is a global leader in the development of nanomedicine drugs.

Their unique nanoviricide® platform technology defines a novel mechanism enabling first-in class drugs against vir-uses.

A nanoviricide is designed to specifically attack enveloped vir-us particles, on the same sites that they use to bind to cells, and dismantle them, blocking reinfection cycle, going beyond what antibodies and immunotherapeutics do.

It can also be designed to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity.

The company's unique biomimetic approach enables creation of drugs that a vir-us would be highly unlikely to escape due to mutations.

NanoViricides is one of the few biopharma companies with its own multi-kilogram-scale c-GMP capable manufacturing facility for the drug substance as well as drug product.

This facility is fully owned by the Company with no mortgage and is a major asset.

This flexible, multi-product pilot plant can supply drug product for all of their programs through human clinical trials.

Their cGMP manufacturing ability enables substantial time and cost savings in their drug development programs.

Further, it is capable of production for initial marketing, enabling early revenues upon drug approval, of about $100Mn~$500Mn per year.

Company Sources: Presentation. Website.

As for why someone might want to pay attention to NanoViricides, Inc. (NYSE American: NNVC) right now, here's 6 immediate reasons...

#1. Innovative technology: Their nanoviricide technology could potentially offer a new approach to treating viral infections.

A nanoviricide is created by chemically attaching a vir-us-binding ligand, derived from the binding site of the vir-us on its cell surface receptor, to a nanomicelle flexible polymer. This binding site does not change significantly when a vir-us mutates.

Tailor-made design and selection of (1) the vir-us-binding ligand; and (2) the backbone "nanomicelle," separately, allows the company to rapidly optimize drug candidates (a) against a number of vir-uses, (b) for desired pharmacokinetic characteristics (e.g. sustained effect), and (c) for different routes of administration. This versatility is unmatched in the industry.

#2. Broad application: Their platform could potentially be adapted to target various vir-uses, which might be particularly relevant in a post-CV19 world.

#3. Low float: With a float of approximately 15.07Mn shares, volatility potential could be significant on a daily basis.

#4. Measles Cases Are Increasing Globally; M-P-ox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution: Anil R. Diwan, PhD, President and Executive Chairman of the Company, shared:

"NV-387 is a revolutionary antiviral drug that can combat many viral infections. We are advancing it rapidly towards establishing human clinical effectiveness data and regulatory approvals. We believe our M-P-ox and Measles work will enable rapid advancement of the drug, and make a great global impact in large markets fulfilling unmet medical needs."

#5. Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo: Anil R. Diwan, PhD, President and Executive Chairman of the Company shared:

"We are now fully engaged in completing the detailed CTA for the Phase II human clinical trial of NV-387 for the treatment of M-P-OX disease (hMPXV infection) for submission to the DRC Regulatory Agency, namely MSP."

"NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases. NV-387 is designed to mimic human cells to trap and destroy the vi-rus. This single drug can target over 90-95% of human pathogenic vi-ruses due to this biomimicry, which is reminiscent of the antibiotic penicillin that targets a large number of human pathogenic bacteria."

#6. Key Triggered Technical Indicators: At close on Wednesday, NNVC was displaying several triggered technicals over at Barchart.

In fact, we counted a total of 8 triggered across the short, medium, and long term including Barchart's "Trend Seeker" composite indicator.

-----

Coverage is officially initiated on NanoViricides, Inc. (NYSE American: NNVC). If there are any updates necessary, I'll have them out to you quickly.

Talk again shortly.

All the best,

Dane James

Editor Market Pulse Today

(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)

(NYSE American: NNVC) Shares Key Announcement This Morning (Multiple Technicals Triggered)

0 Response to "(NYSE American: NNVC) Shares Key Announcement This Morning (Multiple Technicals Triggered)"

Post a Comment